Hidradenitis suppurativa is a chronic, inflammatory, and often painful skin disease that causes recurring boil-like lumps that may burst into open wounds and cause irreversible scarring, often in the most intimate parts of the body. There are only a few treatment options available for this disease, such as AbbVie's Humira and Novartis' Cosentyx, which affect approximately 1 in 100 people. However, these treatments often offer insufficient relief.
The stock we are bringing to your attention today is that of Avalo Therapeutics Inc. (AVTX), a clinical-stage biotechnology company developing a drug for hidradenitis suppurativa.
For comments and feedback contact: editorial@rttnews.com
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.